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High-Precision Therapeutics through Medicinal Nanoengineering® 
Executive Summary 
 Medicinal Nanoengineering® enables enhanced trafficking 
of drugs to tumors, resulting in better efficacy and 
therapeutic index 
 Demonstrated to improve TI of cytotoxic agents and 
molecularly targeted cancer drugs 
 Physicochemical and biopharmaceutical properties of many 
oncology compounds (marketed and developmental) are 
extremely compatible with the BIND platform 
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BIND Medicinal Nanoengineering platform 
Low COGS 
Expanded Therapeutic Index 
Clear Regulatory Path 
Expanded Indications and Lifecycle 
High Barriers to Generics 
Enabling of Difficult APIs 
New Graphic   
 
High drug concentrations in 
target tissues 
 - Long circulating half-life 
 - Tunable biodistribution 
 - Immune system evasion 
 - Dual targeting mechanisms 
 
Unmodified API 
 
Wide range of APIs 
 
FDA approved, 
biocompatible, biodegradable 
polymers 
 
Robust, reproducible and 
scalable manufacturing 
Best in class 
Drugs 
Controlled release polymers 
API 
Stealth and protective layer 
Targeting ligand 
BIND Targeted 
Nanoparticle 
Features 
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Our first clinical stage product:  BIND-014 
 BIND-014 goal: Best-in-class taxane 
 
 Target: PSMA 
o Clinically validated target with widespread 
solid tumor expression 
o Prostate cancer cell surface 
(95% of patients) 
o Non-prostate solid tumor neovasculature 
(> 80% of breast, colorectal, renal and  
bladder cancer patients) 
 
 Payload: Docetaxel 
o Approved for prostate, breast, lung, gastric, and head/neck cancers 
 
 Development pathway 
o Well-defined 505(b)(2) registration pathway 
o Ongoing Phase 1 clinical study in solid tumors 
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BIND-014 and Taxotere PK 
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COMPANY CONFIDENTIAL INFORMATION 
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Tumor Bearing Mice 
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BIND-014 
DTXL                 
BIND-014 and Taxotere tumor targeting 
BIND-014 efficacy and tolerability 
Spontaneous PSMA+ Prostate 5mg/kg (Q4D x 2)  
  
Body Weight Data for LNCaP  
5mg/kg (Q4D x 4)  
  
BIND-014 Phase 1 clinical study 
 BIND-014-001 
o A Phase 1 Open Label, Safety, Pharmacokinetic and Pharmacodynamic 
Dose Escalation Study of BIND-014, Given by IV Infusion to Patients 
with Advanced or Metastatic Cancer 
 
 Investigators: Dan Von Hoff (Tgen), Pat LoRusso (Karmanos), Peter 
Eisenberg (Marin Cancer Center) 
 
 Primary objective 
o Assess the dose limiting toxicities of BIND-014, determine the maximum 
tolerated dose when given once every three weeks, and select a dose 
for use in Phase 2 clinical studies 
 Secondary objectives 
o Characterize the PK profile of BIND-014 
o Assess any preliminary evidence of anti-tumor activity 
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Medicinal nanoengineering of partner kinase inhibitor 
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DESIGN 
Combinatorial libraries of 
targeted nanoparticles to  
map critical properties 
In vitro and in vivo 
optimization 
Scale up for pre-clinical, 
clinical and commercial 
development 
ENGINEER MANUFACTURE 
Broad and robust IP portfolio 
BIND manufacturing trade secrets 
BIND Medicinal Nanoengineering platform 
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BIND overview 
Robert Langer, ScD – MIT, David H. Koch Institute Professor 
Omid Farokhzad, MD – Harvard Medical School, Associate Professor 
 
 
   
 
BIND was founded in 2006 by two pioneering academic investigators… 
…and has been backed by leading VC firms and US government 
Scott Minick – President & CEO 
ARCH Venture Partners, SEQUUS, Baxter, Lilly 
 
Jim Wright, PhD – CSO 
Infinity, Millennium, Alkermes, BI 
 
Ed Schnipper, MD – CMO 
ALZA, SEQUUS, Roche 
 
Andrea Franz – CFO 
Franz Assoc., ESS, Groundwater Technologies 
Jeff Hrkach, PhD – SVP, Pharm Sci 
Momenta, Alkermes, AIR 
 
Steve Zale, PhD – VP, Development 
Alkermes, Sepracor 
 
Paul Burgess, JD – VP, IP 
J&J, TransForm, Genetics Institute 
 
Dan Koerwer –  Head, Market & Bus. Dev. 
Eidetica Biopharma, Biogen Idec 
…is led by an experienced team of successful entrepreneurs and drug developers… 
 
DHK Investment 
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Magic Nano-Bullets 
Advances in nanotechnology could make drug 
delivery far more accurate and effective  
BIND high-precision therapeutics  
through Medicinal Nanoengineering 
MIT Technology Review 2010 
50 Most Innovative Companies 
MIT Technology Review 2011 
50 Most Innovative Companies 
Cancer treatment dodges immune system 
